- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04036136
Development of a Novel Transdiagnostic Intervention for Anhedonia - R33 Phase
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Deficits in motivation and pleasure, together referred to as anhedonia, are implicated in a number of psychiatric illnesses, including mood and anxiety disorders, substance-use disorders, schizophrenia, and attention-deficit/hyperactivity disorder. As a result, constructs related to anhedonia are central to the NIMH Research Domain Criteria (RDoC) project. Anhedonia is often one of the most difficult psychiatric symptoms to treat and thus represents a critical endophenotype and vulnerability factor for a range of psychiatric disorders. Given the centrality of anhedonia to a large number of psychiatric disorders, improved interventions to treat motivation and pleasure are critical for these disorders. The overall goal of this R61/R33 project is to develop a novel transdiagnostic treatment for anhedonia, called Behavioral Activation Treatment for Anhedonia (BATA). This new intervention is designed to treat anhedonia by emphasizing supported engagement with personally relevant goals and reducing avoidance behaviors. Consistent with the objectives and milestones outlined in RFA-MH-16-406 ("Exploratory Clinical Trials of Novel Interventions for Mental Disorders"), in the R61 phase of this trial that lasted from June 22, 2017-July 31, 2019, the investigators proposed to use an experimental therapeutics approach to first evaluate mesocorticolimbic target engagement by this treatment in a transdiagnostic sample characterized by clinically impairing anhedonia (Aim 1). Specifically, the investigators examined the effects of this treatment, relative to an active comparison treatment, on caudate nucleus activation during reward anticipation and rostral anterior cingulate cortex activation during reward outcomes using ultra-high field (7T) functional magnetic resonance imaging. The investigators also used fMRI to determine the optimal dose of the intervention (Aim 2).
In the current R33 phase of the study, which begins recruitment 8/1/2019, the investigators plan to evaluate the effects of the optimal dose of this new treatment, versus an active comparison treatment, on anhedonic symptoms and functional outcomes (Aim 3), behavioral indicators of reward sensitivity (Aim 4), and neural indicators of reward processing (Aim 5).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jessica Kinard, PhD
- Phone Number: 919-966-3594
- Email: jessica.kinard@cidd.unc.edu
Study Contact Backup
- Name: Lisalynn Kelley
- Email: lisalynn.kelley@duke.edu
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7255
- UNC-Chapel Hill School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18-50 years old and treatment seeking;
- SHAPS scores ≥ 20, corresponding to clinically significant anhedonia;
- Clinician's Global Impression Scale-Severity score (CGI-S) > 3 to assure a clinically impaired sample;
- Seeking treatment for anhedonia (i.e., referred from an outpatient clinic or responded to an advertisement for anhedonia treatment; endorses desire for treatment during screening).
Exclusion Criteria:
- Those for whom medication management is the primary gold-standard treatment, including those with bipolar disorder/mania, schizophrenia spectrum, and other psychotic disorders;
- Prior treatment with behavioral activation therapy for depression or mindfulness-based treatments (those with exposure to other forms of psychotherapy, e.g., supportive therapy, will be eligible);
- Those who may have difficulty understanding the cognitive components of BATA, including those with intellectual disability, neurocognitive disorders, and dissociative disorders;
- Feeding and eating disorders which may have confounding effects on the fMRI signal;
- Substance Use Disorders given confounding effects of substances of abuse on the fMRI signal;
- Suicidal intent and plan;
- Psychotropic medication use in the past 4 weeks (8 weeks for fluoxetine) and/or current psychotherapy. Participants must be medication-free at study entry; study personnel will not supervise medication taper for the purpose of the study, but those who taper under the supervision of their regular provider will be eligible;
- Currently pregnant, as measured by urine pregnancy screen immediately before MRI scans;
- Positive urinalysis screen for cocaine, marijuana, opiates, methadone, amphetamines, and benzodiazepines (conducted on-site via Biosite Triage Meter Plus) at study entry.
- No neurological conditions (e.g., history of stroke, seizure, or TBI); Contraindications for fMRI imaging: Metal in the body, dental work that is not fillings or gold, any tattoos, any metal in the body, any metal injury - especially those to the eyes, any other type of implant unless they are 100% plastic.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Behavioral Activation
Treatment will consist of 15 weekly 45-minute sessions.
Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced.
Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals.
Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
|
Treatment will consist of 15 weekly 45-minute sessions.
|
Active Comparator: Mindfulness Treatment
BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA.
Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience.
MBCT will be administered in an individual format.
The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014.
Treatment will be compromised of 15 weekly 45-minute sessions.
|
Treatment will consist of 15 weekly 45-minute sessions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline to Week 15 in Snaith-Hamilton Pleasure Scale Score
Time Frame: Baseline, 15 weeks
|
The Snaith-Hamilton Pleasure Scale (SHAPS), a well-validated 14-item questionnaire will be used to assess hedonic capacity.
The sum of the 14 items scores ranges from 0 to 56.
A higher score represents more anhedonic symptoms.
|
Baseline, 15 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline to Week 15 in Neural Activation
Time Frame: Baseline, 15 weeks
|
Neural activation assessed by Functional Magnetic Resonance Imaging (fMRI) during Monetary Incentive Delay (MID) task
|
Baseline, 15 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gabriel S Dichter, PhD, UNC-Chapel Hill
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-2268b
- R61MH110027 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anhedonia
-
CEN BiotechCEN Nutriment; Biovet Conseil; Amadeite SASCompletedAnhedonia in Healthy Volunteers
-
Maastricht UniversityAristotle University Of Thessaloniki; P1vital Products LTD.; Biotrial; University... and other collaboratorsCompletedDepression | Schizophrenia | Motivation | Anhedonia, Physical | Anhedonia, Social | Negative Symptoms With Primary Psychotic DisorderGermany, Greece, Netherlands, Spain
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH); Duke UniversityCompletedAnhedoniaUnited States
-
University of OxfordRecruiting
-
University of ManitobaEnrolling by invitation
-
The University of Texas Health Science Center,...Emory UniversityCompleted
-
Jiangsu Province Nanjing Brain HospitalNot yet recruiting
-
University of New MexicoNational Institute of Mental Health (NIMH)Completed
-
University of OxfordCompleted
Clinical Trials on Behavioral Activation
-
New York State Psychiatric InstituteCallen-Lorde Community Health CenterCompletedHIV Infection | FatigueUnited States
-
Hospital Miguel ServetCompletedMajor Depressive DisorderSpain
-
Stanford UniversityCompletedDepression | Major Depressive Disorder | MDDUnited States
-
University of WashingtonNational Institute of Mental Health (NIMH)Completed
-
Central Arkansas Veterans Healthcare SystemNational Center for PTSDWithdrawn
-
Stanford UniversityCompletedDepression | Major Depressive Disorder | MDDUnited States
-
Seinajoki Central HospitalTampere UniversityCompletedAnxiety Disorders | Major Depression | Dual Diagnosis | Substance Related DisordersFinland
-
Northwestern UniversityCompletedDepression | Anhedonia | Bipolar DisorderUnited States
-
University of WashingtonNational Institute of Mental Health (NIMH); University of South Florida; Weill...Recruiting
-
University of AarhusRecruiting